Business Context and Reporting Period
Company: Firefly Neuroscience, Inc. (Ticker: AIFF)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Firefly is an AI-driven medical device company focused on precision neuroscience. Its core offering is the Firefly Platform, which includes the FDA-510(k) cleared Evoke System (hardware) and a cloud-based analytics engine. The platform captures electroencephalographic (EEG) and event-related potential (ERP) data to provide clinicians with objective brain health assessments. As of December 31, 2025, the Evoke System was deployed in over 85 clinical sites in the U.S.
Key Corporate Events:
- Merger: Completed a reverse merger with WaveDancer, Inc. on August 12, 2024, becoming a public company.
- Acquisition: Acquired Evoke Neuroscience, Inc. on April 30, 2025, for approximately $6.2 million (cash and stock), significantly expanding its hardware capabilities and customer base.
- Strategic Shift: Discontinued the legacy BNA software platform and Zeto headsets following the Evoke acquisition, resulting in asset impairments.
Key Financial Metrics
| Metric ($ in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $1,142 | $108 |
| Gross Profit | $645 | $108 |
| Operating Loss | $(8,856) | $(10,054) |
| Net Loss | $(19,882) | $(10,460) |
| Cash Flow from Operations | $(8,194) | $(6,155) |
| Cash and Equivalents (Year End) | $2,747 | $1,810 |
| Accumulated Deficit | $(111,615) | $(87,084) |
Liquidity and Debt: The company reported no long-term debt as of December 31, 2025. Current liabilities totaled $2.8 million, primarily consisting of accounts payable and accrued liabilities. The company has an accumulated deficit of $111.6 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 957% to $1.142 million, driven primarily by the inclusion of Evoke Neuroscience operations following the April 2025 acquisition.
- Operating Expenses: Total operating expenses decreased by 6.5% to $9.5 million. This reduction was due to lower R&D and Selling/Marketing expenses (partially offset by higher G&A costs related to D&O insurance and accrued fees from a cancelled equity line of credit).
- Impairment Charges: The company recognized $251,000 in impairment charges related to the write-down of legacy BNA software and Zeto headsets, which were deemed obsolete following the strategic pivot to the Evoke platform. This was a decrease from $874,000 in impairments in 2024.
- Non-Operating Losses: Other expenses increased significantly to $11.0 million (from $0.4 million in 2024), largely due to a $9.4 million loss on the change in fair value of a derivative liability and a $1.4 million loss on the settlement of a convertible promissory note.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The independent auditor has issued an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern. This is due to recurring losses, an accumulated deficit of $111.6 million, and negative cash flows from operations. Management's plan to mitigate this includes raising additional capital through equity offerings and debt financing.
Recent Capital Raises (Subsequent Events):
- March 2026 Private Placement: Closed an initial tranche raising $2.25 million with an option for investors to purchase up to an additional $18 million within 30 days.
- ATM Facility: Established an At-The-Market offering program to sell up to $7.4 million of common stock.
Key Risks:
- Geopolitical: Operations in Israel are exposed to risks from the ongoing conflict involving Iran, Israel, and the U.S., including potential employee call-ups to military reserve duty and infrastructure disruptions.
- Regulatory: As a medical device company, Firefly faces rigorous FDA and international regulatory requirements. The acquisition of Evoke increased the complexity of regulatory compliance.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding IT general controls and segregation of duties. Remediation is expected to be completed in 2026.
- Intellectual Property: The company relies on Israeli Innovation Authority (IIA) grants, which impose royalty obligations and restrictions on transferring technology outside of Israel.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.75 million cash balance (as of year-end) plus the $2.25 million raised in March 2026 against the company's monthly burn rate and operating expenses.
- Revenue Quality: Assess the sustainability of the 957% revenue growth, specifically determining how much is recurring subscription revenue from the Evoke platform versus one-time equipment sales.
- Derivative Liabilities: Review the terms of outstanding warrants and convertible notes to understand potential future dilution and the risk of further fair value adjustments impacting the income statement.
- Internal Control Remediation: Monitor the progress of remediation efforts for the identified material weaknesses in internal controls over financial reporting.
- Geopolitical Exposure: Evaluate the specific impact of the Israel conflict on the company's R&D capabilities, given that a portion of its workforce and historical IP development is located there.